Eric Karas - 01 Jul 2025 Form 4 Insider Report for ARS Pharmaceuticals, Inc. (SPRY)

Reporting relationship: Chief Commercial Officer
Issuer ticker: SPRY
Reported as of: 01 Jul 2025
Net transaction value: -$232,360
SEC form: 4
Accepted by SEC: 03 Jul 2025, 16:21:24 UTC
Prior SEC filing: 20 Jun 2025
Next SEC filing: 05 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Kathleen Scott, Attorney-in-Fact

Key filing fact

Eric Karas filed Form 4 for ARS Pharmaceuticals, Inc. (SPRY) on 03 Jul 2025.

Key facts

This page summarizes Eric Karas's Form 4 filing for ARS Pharmaceuticals, Inc. (SPRY).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 03 Jul 2025, 16:21.

Change

Previous filing in this sequence was filed on 20 Jun 2025.
Current net transaction value: -$232,360.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001951287 Primary reporting owner

Karas Eric

Relationship: Chief Commercial Officer
Address: C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO
Signature: /s/ Kathleen Scott, Attorney-in-Fact
Signature date: 03 Jul 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SPRY transaction

Common Stock

Options Exercise

Transaction value: $22,500
Shares: +15,000
Change %: +145%
Price: $1.50
Shares after: 25,315
Date: 01 Jul 2025
Ownership: Direct
Footnotes: F1

SPRY transaction

Common Stock

Sale

Transaction value: $254,860
Shares: -15,000
Change %: -59%
Price: $16.99
Shares after: 10,315
Date: 01 Jul 2025
Ownership: Direct
Footnotes: F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SPRY transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -15,000
Change %: -2.7%
Price: $0.000000
Shares after: 544,588
Date: 01 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,000
Exercise price: $1.50
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

Includes 2,619 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on June 30, 2025.

Footnote F2

The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2024.

Footnote F3

The weighted average sale price for the transaction reported was $16.9907, and the range of prices were between $16.71 and $17.31. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Footnote F4

Immediately exercisable.